The FDA Vaccines and Related Biological Products Advisory Committee agreed on the efficacy, immunogenicity and safety data of Merck & Co Inc’s . The clinical trials support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and men aged 9 to 26 years for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

Merck’s cervical vaccine Gardasil has been approved by the U.S. Food and Drug Administration for protection against vaginal and vulvar cancers caused by Human Papilloma Virus (HPV) types 16 and 18 for females aged from 9 to 26. The vaccine is already used for prevention of cervical cancer, approval for which was given by FDA in 2006. Gardasil does not work if you are already infected when you become vaccinated. Women should undergo regular screening to get precancerous lesions detected and receive treatment before cancer.